Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Bevacizumab exerts anti-angiogenic effects in cancer patients by inhibiting vascular endothelial growth factor (VEGF). However, its use is still limited due to the development of resistance to the treatment. Such resistance can be regulated by various factors, although the underlying mechanisms rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsuhashi, Atsushi, Goto, Hisatsugu, Saijo, Atsuro, Trung, Van The, Aono, Yoshinori, Ogino, Hirokazu, Kuramoto, Takuya, Tabata, Sho, Uehara, Hisanori, Izumi, Keisuke, Yoshida, Mitsuteru, Kobayashi, Hiroaki, Takahashi, Hidefusa, Gotoh, Masashi, Kakiuchi, Soji, Hanibuchi, Masaki, Yano, Seiji, Yokomise, Hiroyasu, Sakiyama, Shoji, Nishioka, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686833/
https://www.ncbi.nlm.nih.gov/pubmed/26635184
http://dx.doi.org/10.1038/ncomms9792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686833/
https://www.ncbi.nlm.nih.gov/pubmed/26635184
http://dx.doi.org/10.1038/ncomms9792

Ejemplares similares